Instaflex D

Quick links to important sections

Instaflex D

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Instaflex D

Quick Facts

Property Description
Active ingredient Diclofenac
Form Oral Tablet (Systemic)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of Pain, Inflammation, and Fever
Origin Synthetic Compound

What Type of Medicine Is Instaflex D?

Instaflex D is a synthetic medicinal preparation primarily containing the active ingredient Diclofenac, which belongs to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification indicates its function in reducing pain, inflammation, and fever.

The drug is a derivative of phenylacetic acid, produced via chemical synthesis, and is not naturally sourced. Instaflex D is typically presented as an oral dosage form, such as a tablet or capsule, designed for systemic administration throughout the body. The specific tablet formulation of Instaflex D distinguishes it as an oral option for patients requiring relief, contrasting with localized topical preparations.

Instaflex D Composition and Purpose

Instaflex D is formulated as a single-ingredient product, with Diclofenac serving as the sole therapeutic entity, accompanied by pharmaceutical excipients necessary for the tablet structure. Its high-level mechanism of action involves inhibiting the synthesis of prostaglandins.

The core physiological action is the non-selective inhibition of the Cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins—the chemical mediators that drive pain, fever, and the inflammatory response. This mechanism results in reduced pain and decreased inflammation. Consequently, the medication's fundamental purpose is to mitigate the chemical processes that cause discomfort and physical swelling, supporting general systemic relief in patients experiencing inflammatory symptoms.

Regulatory References

  1. COX Inhibitors (StatPearls - NCBI Bookshelf)

What side effects are possible with Instaflex D?

Possible Side Effects and Safety Information

Instaflex D (Diclofenac) has an official safety profile primarily characterized by potential effects on the gastrointestinal and cardiovascular systems, as documented in regulatory sources like the FDA and EMA. Adverse reactions are classified by both frequency and the System-Organ Class (SOC) affected.

Officially Documented Adverse Reactions

The most frequently reported effects (classified as Common) involve the Gastrointestinal system, including nausea, vomiting, dyspepsia, and abdominal pain, along with Nervous System effects such as headache and dizziness. Less frequently (classified as Uncommon or Rare), reactions may involve the Hepato-biliary system (elevated liver enzymes) and severe dermatological or renal issues.

Serious Safety Considerations

Official regulatory labeling includes mandatory warnings regarding Serious Adverse Events. These include the potential for Cardiovascular (CV) Thrombotic Events, such as myocardial infarction and stroke, which may occur early in treatment and increase with duration of use. A further critical risk is Serious Gastrointestinal Adverse Events, including bleeding, ulceration, and perforation of the stomach or intestines.

Population-Specific Safety Notes

The regulatory label notes that Older Adults may be at greater risk for serious gastrointestinal adverse events. Furthermore, Instaflex D is specifically contraindicated in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. The medicine is also contraindicated in the setting of prior coronary artery bypass graft (CABG) surgery and in individuals with known hypersensitivity reactions to aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Instaflex D (Diclofenac) overdose documents acute toxicity primarily affecting the gastrointestinal (GI), central nervous (CNS), and renal systems. Manifestations commonly reported include nausea, vomiting, stomach pain, dizziness, drowsiness, and ringing in the ears (tinnitus). Severe GI signs, such as black or bloody stools, or little to no urine output, require immediate attention.

Overdose can lead to serious, life-threatening outcomes. Regulatory labeling identifies risks such as severe gastrointestinal bleeding, ulceration, and perforation. Severe neurological events, including coma and seizures, are documented, as are acute renal failure and the potential for cardiovascular thrombotic events like myocardial infarction or stroke.

Because no specific antidote is known for Instaflex D overdose, immediate management is restricted to symptomatic and supportive care. Procedures such as gastric lavage and the administration of activated charcoal may be considered by medical professionals. Continuous monitoring of vital signs, including ECG and laboratory tests, is typically required.

It is an official regulatory mandate to seek immediate medical attention for any suspected overdose. Urgent medical help must be sought if symptoms are severe, such as signs of internal bleeding, loss of consciousness, or difficulty breathing. Specific overdose considerations are noted for the elderly and individuals with underlying conditions like asthma or kidney impairment, where adverse outcomes may be more serious.

Therapeutic Uses of Instaflex D

What Instaflex D Treats: Main Uses and Benefits

Instaflex D may be used for symptomatic relief related to inflammatory or irritative states and chronic pain conditions. The medication is commonly used to help manage the overall symptom burden across several clinical domains.

This medication is generally applicable within clinical settings that involve acute or disruptive symptom patterns, and is relevant for easing symptoms associated with conditions such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Primary Dysmenorrhea, and Acute Migraine Attacks.

Instaflex D is commonly used to address groups of symptoms that may become intense or disruptive, such as pain, swelling, and stiffness. This approach supports the patient during difficult episodes and contributes to maintaining functional stability.


Quick Fact Symptom Focus
Symptom Focus Inflammation and Pain in musculoskeletal disorders.
Episodic Pain Focus Pain during migraine or menstrual cramps.
Systemic Symptom Focus Supports and may assist with easing fever and generalized physical discomfort.

This use contributes to easing the overall symptom load and may assist with maintaining a sense of stability during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Diclofenac

Eligibility and Restrictions for Use

Who can and cannot use Instaflex D?

Instaflex D (Diclofenac) is primarily intended for use by the adult population (18 years and older). Official regulatory documents establish several absolute exclusions defining who must not use this medicine.


Contraindicated Populations

Instaflex D is contraindicated for patients with a known hypersensitivity to the drug or any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those who experience asthma or hives after taking aspirin. Use is also formally prohibited in patients with active gastrointestinal bleeding or ulceration, advanced renal failure, and those with established severe heart disease (e.g., Ischaemic Heart Disease, NYHA Class II-IV Congestive Heart Failure). Additionally, the medicine is contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery.


Age and Condition Restrictions

Safety and efficacy are not established for children younger than 12 years. Use in older adults requires caution due to the higher likelihood of age-related issues. For pregnant women, the medicine is contraindicated at 30 weeks gestation and later; use is strictly limited during 20 to 30 weeks gestation. Patients with mild hepatic or renal impairment or a history of GI issues should only use the medicine with caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Instaflex D (Diclofenac) based on regulatory information.


Interaction Scope

Category Official Finding
Medicinal product categories with documented interactions Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticoagulants, Oral Corticosteroids, SSRIs/SNRIs, ACE Inhibitors, ARBs, Diuretics, and CYP2C9 Inhibitors.
Specific interacting medicines (if explicitly listed) Aspirin (at analgesic/anti-inflammatory doses), Voriconazole, Lithium, Digoxin, Methotrexate.
Mechanistic basis of interactions (only if stated in label) Diclofenac is primarily metabolized by the CYP2C9 enzyme. The co-administration of CYP2C9 inhibitors increases Diclofenac’s exposure. Interactions with Lithium and Digoxin occur due to reduced renal clearance of the co-administered drug.
Population-specific interaction notes (if applicable) The concurrent use with ACE Inhibitors, ARBs, or Diuretics requires close monitoring in elderly patients and those with compromised renal function due to the potential for renal function deterioration.
Interaction-related restrictions Co-administration with other NSAIDs or analgesic doses of Aspirin is not generally recommended due to the enhanced risk of serious gastrointestinal (GI) adverse events. Alcohol consumption increases the risk of GI bleeding and ulceration.

Resulting Interaction Structure

Regulatory documents establish that the drug's interaction profile is defined by pharmacokinetic alterations and pharmacodynamic reinforcement. Instaflex D can significantly increase the plasma concentrations of co-administered narrow therapeutic index drugs like Lithium and Digoxin by reducing their clearance. Furthermore, co-administration with other antiplatelet agents, Anticoagulants, or SSRIs/SNRIs results in an additive risk of serious GI bleeding. Diclofenac is also officially noted to diminish the antihypertensive effects of ACE Inhibitors and Diuretics.

Mechanism of Action

Molecular Target: Enzyme Inhibition

Instaflex D (Diclofenac) functions as a non-selective, competitive, reversible inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and inducible COX-2 isoforms. This mechanism blocks the active site of the enzymes, thereby restricting the metabolic conversion of the precursor molecule, arachidonic acid, into prostanoids.

Pathway Cascade: Modulating Prostaglandin Synthesis

The primary consequence of COX inhibition is a substantial, systemic reduction in the synthesis of prostaglandins, specifically Prostaglandin E2 (PGE2). This action interferes with the chemical cascade that drives the body's inflammatory response by limiting the impact of mediator activity at the site of tissue changes.

Physiological Effect: Dampening Signaling

The resulting lower concentration of PGE2 leads to a dual physiological effect: it reduces the chemical sensitization of peripheral pain-sensing nerves (nociceptors) and suppresses PGE2 production in the hypothalamus. This modulation of both peripheral and central signaling adjusts the activity in pain and temperature regulation pathways.

Dosage and Administration Information

Instaflex D is administered via the oral route for systemic use, typically presented as a tablet or capsule, including delayed-release (DR) and extended-release (ER) formulations. The primary principle for use is to maintain the lowest effective dosage for the shortest duration consistent with treatment goals. The continuous need for therapy is subject to periodic re-evaluation.

Official Administration Patterns

The standard daily dosage for chronic conditions, such as arthritis, generally falls between 100 mg and 200 mg, administered in divided doses. The frequency depends on the specific formulation: DR tablets are typically taken two to three times daily, whereas ER tablets are formulated for once-daily use. The total daily dose must not be exceeded.

Handling and Contextual Constraints

Tablets formulated for delayed- or extended-release must be swallowed whole with liquid and must not be crushed, split, or chewed, as this compromises the intended release mechanism. While the medication can be taken with food to reduce gastrointestinal discomfort, doing so may delay the onset of absorption, a factor relevant to the speed of relief. If a dose is missed, the missed dose should be skipped and the regular schedule resumed, rather than doubling the next dose.

Population Rules

For older adults, the use of the lowest effective dose is required. Dosing is generally not recommended in cases of severe renal or hepatic impairment. Furthermore, the various oral forms of diclofenac are not considered bioequivalent and should not be interchanged on a milligram-for-milligram basis.

Recent Clinical Evidence

Research evidence / Overview of Studies for Instaflex D

The research exploring Instaflex D (Diclofenac Oral Tablet) is based on studies that examine how symptoms change over time across different conditions. Scientific evaluations rely on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews to understand the available evidence. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.


Evidence for Managing Chronic Inflammatory Conditions

Research has explored the use of Instaflex D for conditions marked by functional limitations and outcomes linked to inflammatory states, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

Findings describe patterns observed in the studies, which included descriptions of patient-reported pain scores and physical function over the observation periods. Studies report how symptoms evolved in adult and older adult populations during the mid-term duration of the trials. However, long-term outcomes related to the sustained patterns of symptom measurement are not fully established for periods exceeding a few months.


Evidence for Managing Ankylosing Spondylitis (AS)

Evidence for Ankylosing Spondylitis included Short-term Comparisons for symptomatic control and specialized Long-term Trials designed to monitor functional measures and radiographic progression of the spine. Short-term trials reported the values of measured pain and function scores. Research exploring long-term outcomes described patterns where findings were mixed or numerically varying regarding whether one specific dosing pattern is linked to long-term radiographic progression. Certainty remains low in this area.


Evidence for Acute, Episodic Pain Conditions

Research for acute uses, such as Acute Migraine Attacks and Primary Dysmenorrhea, is typically derived from Systematic Reviews of short-term, placebo-controlled trials.

Studies explored outcomes describing episodic changes, including the time to achieving pain-free status and measurements of rescue medication usage. Research provides insight into what has been observed so far in the short term, but the results apply only to the populations studied.


Evidence Gaps and Areas of Scientific Uncertainty

Key limitations include that long-term effects are not fully established for sustained symptom management across all indications. Data for certain specific groups, such as children, pregnancy-related populations, or those with multiple pre-existing health issues, remain insufficient, and comparative evidence is lacking against many non-drug treatment options.

Frequently Asked Questions (FAQ)

Common questions about Instaflex D (FAQ)


Q: How quickly should I expect to notice the effects of Instaflex D?

The time it takes for Instaflex D to start working can vary based on how the tablet is formulated, such as whether it is an extended-release or delayed-release form. According to official product information, taking the medicine with food may delay the rate at which the medication is absorbed by the body.


Q: What are the observable signs that Instaflex D is having its intended effect?

The intended effects of Instaflex D are typically observed as a relief of pain and a reduction in inflammation. Studies indicate that these effects relate to a decrease in swelling and an overall improvement in physical function associated with the condition being treated.


Q: Is Instaflex D safe to use for older adults?

Instaflex D is used with caution in older adults, as regulatory documents indicate this population may have an increased risk of certain serious side effects, particularly those affecting the gastrointestinal tract. Official guidance emphasizes the use of the lowest effective dosage for the shortest necessary duration consistent with treatment goals.


Q: Are there separate long-term observational studies available for Instaflex D use?

Official research summaries indicate that the long-term effects for sustained symptom management are not fully established for all conditions treated with Instaflex D. Ongoing data collection and post-market surveillance are utilized by regulatory agencies to monitor the drug's safety profile over extended periods.


Q: What patient demographics (age, sex, ethnicity) were included in the primary Instaflex D trials?

Official clinical trials primarily included adult and older adult populations. Regulatory documents contain specific details regarding the age ranges, sex, and ethnicity of participants, which can be found in the comprehensive study summaries available to health authorities.


Q: How is Instaflex D different from similar over-the-counter supplements?

Instaflex D is chemically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is typically available by prescription only. This is due to its potency and the associated potential for serious side effects, such as those affecting the cardiovascular system, which require medical supervision.


Q: Do I need a prescription to get Instaflex D?

Yes, the oral formulations of Instaflex D containing Diclofenac are regulated as prescription-only medications. This classification means they must be dispensed by a pharmacist following authorization from a licensed healthcare provider.


Q: How long does one dose of Instaflex D typically last in the body?

The rate at which Instaflex D is eliminated is described by its terminal half-life, which is approximately two hours in the plasma. This means it takes about two hours for the body to reduce the amount of the drug in the blood by half, though the duration of the clinical effect may be longer.


Q: Is weight gain listed as a potential side effect of Instaflex D?

Official labeling notes that unexplained weight gain or swelling (edema) can be a potential sign of a serious side effect, such as fluid retention or a worsening heart condition. The labeling indicates that signs of a serious effect should prompt immediate attention from a healthcare provider.


Q: If a minor side effect of Instaflex D persists, what is generally advised?

Official guidance documents state that if a common or minor side effect persists or becomes bothersome, or if there is any concern, patients should seek input from a healthcare provider or pharmacist.


Q: Why is headache sometimes listed as a side effect of Instaflex D?

Headache is listed as a common side effect of Instaflex D, a type of nonsteroidal anti-inflammatory drug (NSAID). Research indicates that although these medicines are used to relieve pain, taking them too frequently may lead to a phenomenon known as medication-overuse headache (or rebound headache).


Q: What are the warning signs of a serious allergic reaction to Instaflex D?

The warning signs of a serious allergic reaction to Instaflex D can include physical changes such as hives, swelling of the face, lips, throat, or tongue, and difficulty breathing or swallowing. The labeling indicates that symptoms suggesting a serious reaction warrant immediate attention from a healthcare provider.


Q: Is Instaflex D a controlled substance?

No, Instaflex D is a Nonsteroidal Anti-inflammatory Drug (NSAID) containing Diclofenac. According to government classifications, this medication is not listed as a controlled substance and does not have the scheduling restrictions applied to other types of regulated drugs.


Q: What percentage of patients typically experience the reported side effects of Instaflex D?

Regulatory documents generally describe the frequency of side effects using categories like Common, Uncommon, or Rare. For instance, common side effects typically occur in up to 10% of patients. A single overall percentage is not provided, as the risk varies depending on the specific adverse event.


Q: Can I take Instaflex D if I already take a vitamin supplement?

Official guidance states the importance of a healthcare provider being aware of all concurrent medicines, herbal remedies, and supplements taken by the patient to assess for potential interactions or risks.


Q: Are there specific foods or beverages that should be avoided when taking Instaflex D?

Regulatory documents state that using alcohol concurrently with Instaflex D increases the risk of serious side effects, specifically gastrointestinal bleeding and ulceration. The information notes that no specific food items are generally restricted, although food can delay absorption.


Q: Is Instaflex D considered safe to use during pregnancy or while breastfeeding?

Instaflex D is contraindicated, meaning it must not be used, during the third trimester of pregnancy (30 weeks gestation and later). Official information indicates that the drug is excreted into breast milk; however, available data suggest the levels are low, and many experts consider its use acceptable in lactating women after the neonatal period.


Q: Are there any known effects of Instaflex D on fertility?

Official information indicates that, like other anti-inflammatory medicines, Instaflex D may temporarily affect ovulation in women. This potential effect could make it more difficult to become pregnant. However, this effect is described as being reversible once the medication is discontinued.


Q: Where can I find the official clinical study results for Instaflex D?

The official results and information about clinical trials for Instaflex D are often made publicly available by regulatory agencies. They can typically be found through governmental registries and databases, such as the National Institutes of Health's ClinicalTrials.gov website.


Q: Is Instaflex D approved for use in countries outside of the United States?

Yes, the active ingredient in Instaflex D, Diclofenac, is approved and widely used around the world. It is regulated by major health authorities in many countries, including those governed by the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia.


Q: Does Instaflex D contain any substances that are banned in professional sports?

Regulatory information suggests that the active ingredient in Instaflex D is generally not listed on the prohibited lists of major anti-doping organizations, such as the World Anti-Doping Agency (WADA). However, athletes are advised to be aware of the most current lists provided by their specific sports governing body.


Q: What is the difference between a contraindication and a warning for Instaflex D?

A Contraindication is a circumstance or condition under which Instaflex D must absolutely not be used because the risk of harm significantly outweighs any potential benefit. In contrast, a Warning describes a serious potential hazard or risk that may require special precautions, monitoring, or careful consideration by a healthcare professional.

How should Instaflex D be stored and disposed of?

Instaflex D (Diclofenac Oral Tablet) must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with limited excursions permitted. The official regulatory labeling mandates that the container be kept tightly closed and protected from excessive moisture. It is explicitly stated that the medication should not be stored in a bathroom and must always be kept out of the sight and reach of children.

For disposal of unused or expired tablets, the preferred method is an authorized drug take-back program. If this is not available, the medication must be removed from its original container, mixed with an undesirable substance like coffee grounds or dirt, sealed in a bag or container, and placed in the household trash. Identifying information on the original container must be scratched out.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Instaflex D found in:

A-Z Index: